Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H | ELISA, IP, WB, ICC, IH(P) | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MAB2011 |
| Brand Family | Chemicon® |
| Trade Name |
|
| Description | Anti-Mucin MUC5AC Antibody, clone CLH2 |
| Alternate Names |
|
| Background Information | Mucin-5AC (UniProt: P98088; also known as MUC5-AC, Gastric mucin, Major airway glycoprotein 1, Mucin-5 subtype AC tracheobronchial, Tracheobronchial mucin 1. TBM) is encoded by the MUC5AC (also known as MUC5) gene (Gene ID: 4586) in human. MUC5-AC is a gel-forming glycoprotein of gastric and respiratory tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microorganisms and particles that are subsequently removed by mucociliary system. It is synthesized with a signal peptide (aa 1-27), which is later cleaved off to produce the mature form (aa 28-5654). MUC5-AC undergoes C-O- and N-glycosylated. O-glycosylation occurs on the second and last threonine of the threonine/serine-rich tandem repeats TTPSPVPTTSTTSA. C-mannosylation in the cysteine-rich subdomains may be required for proper folding of these regions and for export from the endoplasmic reticulum during biosynthesis. At its N- and C-termini are larger and more complex domains that are rich in cysteine and are involved in formation of the mucin polymers. These domains include sequences, including the D1, D2, D”, and D3 domains at the N-terminus and the D4, C, and CK domains at the C-terminus. MUC5-AC is overexpressed in a number of carcinomas. (Ref.: Pothuraju, R., et Al. (2020). Mol. Cancer, 19: Article 37; Perez-Vilar, J., et Al. (2004). Glycobiology. 14(4); 325-337). |
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified immunoglobulin. Liquid at 1 mg/mL in 0.02M phosphate buffer, 0.25 M sodium chloride, 0.1% sodium azide, pH 7.6. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-Mucin MUC5AC Antibody, clone CLH2 detects level of Mucin MUC5AC & has been published & validated for use in ELISA, IP, WB, IC, IH(P). |
| Key Applications |
|
| Application Notes | Western blot:Clone CLH2 shows a weak reactivity with a high molecular weight smear characteristic of mucin from a native mucin extract from normal gastric mucosa and from gastric diffuse carcinoma. Typical dilution is 1:100. Immunocytochemistry Immunohistochemistry. Effective on frozen and paraffin sections at 1:1000-1:2000 dilution. ELISA Immunoprecipitation Optimal working dilutions must be determined by end user. |
| Biological Information | |
|---|---|
| Immunogen | Directed against a synthetic peptide of the MUC5AC tandem repeat. |
| Clone | CLH2 |
| Host | Mouse |
| Specificity | Antibody MAB2011 is specific for the MUC5AC tandem repeat of human mucin. No cross reactivity with other peptides from MUC2, 3, 6, or 7. Immunoreactivity of MAB2011 has been detected in the following normal human epithelial tissues: bronchus, endocervix, stomach, and gallbladder. The predominant staining pattern in normal tissues is perinuclear. Antibody reactivity has been observed in foveolar and mucopeptic neck cells of normal gastric mucosa. The expression of MUC5AC has been frequently observed in gastric carcinomas and may be used as a marker of gastric differentiation. The CLH2 antibody shows a weak reactivity with a high molecular weight smear characteristic of mucin from native mucin extract from normal gastric mucosa and from gastric diffuse carcinoma . The antibody was generated by immunizing mice with a synthetic tandem repeat peptide The antibody recognizes the sequence TTSTTSAP within the tandem repeat of MUC5AC (1). It further recognizes glycosylated as well as unglycosylated MUC5AC. |
| Isotype | IgG1 |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P98088 may provide a mechanism for modulation of the composition of the protective mucus layer related to acid secretion or the presence of bacteria and noxious agents in the lumen. Play an important role in the cytoprotection of epithelial surfaces and are used as tumor markers in a variety of cancers. May play a role in epithelial organogenesis. SIZE: 5654 amino acids; 585.57 kDa SUBUNIT: Multimer; disulfide-linked. SUBCELLULAR LOCATION: Secreted. TISSUE SPECIFICITY: Expressed in the regenerative zone of gastric antrum, gastric body mucosa and gastric incisura mucosa. Expressed in the deeper mucous glands of gastric antrum. Overexpressed in Helicobacter pylori infected gastric epithelium. Highly expressed in duodenal Brunners glands, gall bladder, seminal vesicle, pancreatic centroacinar cells and ducts, and periductal glands of the common bile duct. DEVELOPMENTAL STAGE: Early expressed in fetal development and was observed in Brunners glands and pancreatic ducts at 18-19 weeks and in gastric glands at 20 weeks of gestation. Expressed transiently in the nephrogenic zone of the kidney in the early mid-trimester of development. Detected in the epithelium of ureteric buds at 13 weeks and at lower levels from 17 to 23 weeks of gestation. PTM: O-glycosylated. SIMILARITY: SwissProt: P98088 # Contains 1 CTCK (C-terminal cystine knot-like) domain. & Contains 1 TIL (trypsin inhibitory-like) domain. & Contains 3 VWFD domains. |
| Product Usage Statements | |
|---|---|
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |